Author: Andrew Powrie-Smith Date: 05/04/2016 Version: draft

Total Healthcare Spending
Cancer Medicines as a Portion of Total EU Healthcare Spending, 2009
Cancer Drugs

The development of new medicines is shifting The paradigm of treatment towards cure and prevention

The development of new medicines is shifting The paradigm of treatment towards cure and prevention

Cardiovascular disease (CVD) causes more than half of all deaths across the European Region.1
* Pharmacological interventions reduced the risk of developing diabetes by 31% in individuals with impaired glucose tolerance.
Source: Health Advances analysis; 1WHO 2006 Gaining Health: The European Strategy for the Prevention and Control of Noncommunicable Diseases; 2WHO 2005 Preventing Chronic Diseases: A Vital Investment; 3WHO 2010 Delivering for diabetes in Europe; WHO European Guidelines on Cardiovascular Disease Prevention in Clinical Practice, WHO Diabetes Data and Statistics Webpage.
Pharmacological intervention can prevent individuals with impaired glucose tolerance from developing diabetes*1
52 million Europeans are living with diabetes today.3 Up to 80% of people with diabetes will die of CVD.2
Combination drug therapy for CVD (such as aspirin, beta blockers, diuretics and statins) prevents serious complications, and has led to a 75% reduction in myocardial infarction among high risk individuals1 2
Diabetic retinopathy is an important cause of vision loss in Europe, however, through screening and treatment, blindness can be prevented in individuals at high risk1
Preventative medicines developed for cardiovascular disease and diabetes are helping patients avoid serious complications of their disease

The biopharmaceutical industry generates essential economic value in terms of job creation, R&D investment, and medications that improve patient productivity

The biopharmaceutical industry generates essential economic value in terms of job creation, R&D investment, and medications that improve patient productivity